Special Interview

A Conversation with Engineer Seyed Ahmad Mousavi, CEO of Iran Antibiotic Company Engineer Seyed Ahmad Mousavi told Fansalaran: I extend my heartfelt appreciation to all professionals in Iran’s pharmaceutical industry who, despite economic hardship and a severe lack of liquidity and working capital, continue to strive relentlessly to prevent drug shortages in our beloved country. I am hopeful that in 1404 (2025), with serious obstacles removed, pharmaceutical companies and holdings will make significant strides in production, product quality, technological modernization, and GMP-standard upgrades. I especially believe that our own TPICO Holding, under the leadership of Dr. Naderi Alizadeh — a seasoned and capable pharmaceutical executive with extensive supply chain experience — will soon reach its rightful and prestigious position. In fact, even within this short time, we have already seen notable and balanced improvements. As you may know, Iran Antibiotic Company is majority-owned by TPICO. The company was established in 1995 to support Iran’s pharmaceutical infrastructure by producing essential APIs. Production officially started in 2001 with penicillin derivatives. Under Dr. Naderi Alizadeh’s previous leadership, the company saw excellent progress — a path we have continued and expanded upon. Our company’s recent performance, as seen in the Codal system, speaks for itself. Strategic...

A Special Interview with Dr. Mohammad Ahmadi, CEO of Pars Darou Intro: Interviewing a figure who has spent more than a decade safeguarding the assets of Iran’s Social Security Organization and its affiliated economic enterprises—now leading one of the country’s oldest and most reputable pharmaceutical brands—is bound to offer a different kind of perspective. Dr. Mohammad Ahmadi is not media-oriented and rarely accepts interviews. However, in this conversation, we witnessed nothing but sincerity and humility. Open and receptive, he patiently detailed each of his strategic steps, from reforming the product portfolio and launching the cephalosporin site to securing GMP for solid dosage forms, revitalizing exports, acquiring 21 new product licenses, and implementing smart procurement policies. Dr. Mohammad Ahmadi: I studied medicine at Isfahan University of Medical Sciences. Later, I engaged in executive roles within the Ministry of Health, including hospital construction and equipment projects. I served on the boards of pharmaceutical companies like Shahid Ghazi and Sobhan Holding, and proudly spent 12 years in security and oversight departments of the Social Security Organization. Even in those roles, my philosophy was support-oriented, not fault-finding. Before joining Pars Darou on February 18, 2024, I had closely observed the pharma industry due to my medical background....

A Special Interview with Dr. Mohammad Taha Dehghan CEO of Shafie Darou Aria Pharmaceutical Company Note: Great achievements often stem from persistence, scientific passion, and collaboration. The story of Shafie Darou Aria is no exception. Dr. Mohammad Taha Dehghan — a young pharmacist, graduate of Yazd University of Medical Sciences and holder of a Pharmaceutical MBA from the University of Tehran — co-founded the company with two of his classmates, Dr. Hossein Dehghan and Dr. Ghaem Dashti. Today, their company stands as Iran’s only producer of contrast media active pharmaceutical ingredients (APIs). After several years of academic training and hands-on experience in the pharmaceutical industry, we decided to establish a knowledge-based company in Tehran — a company that could channel our expertise directly into Iran’s pharmaceutical sector. And so Shafie Darou Aria was born. We started with a bold goal: to become self-reliant in producing contrast media APIs, particularly Gadoterate Meglumine. Today, we are proud to say that Shafie Darou is the only domestic producer of this critical API, offering a world-class alternative to imported brands. The three of us met during pharmacy school in Yazd. Our friendship was grounded in shared values, a love for science, and a dream to make a meaningful...

A Conversation with Dr. Seyed Mehdi Mousavi — Former CEO of Tamad (Daroupakhsh API Company) Leadership, Innovation, and the Path to Pharmaceutical Excellence in Iran If you want alternatives based on tone and use-case, here are a few options: 📰 For a formal magazine: Special Feature Interview: Dr. Seyed Mehdi Mousavi on Transforming Iran’s API Industry 🧾 For a corporate document or report: Exclusive Interview with Dr. Seyed Mehdi Mousavi, Former CEO of Tamad (2010–2015) 🌐 For an international audience or website: Insights from a Veteran Pharma Leader: Dr. Mousavi on Iran’s API Milestones

Sure! Here's the English translation of the full text, as requested, with no additions: I Owe Everything to the Great Professors of Pharmacy in Iran An exclusive interview with Dr. Amirhossein Hajimiry – Fansalaran Introduction: You really need to meet Dr. Amirhossein Hajimiry in person to understand the true meaning of “character.” We briefly worked together, and one memorable spring afternoon, standing at the entrance of a major pharmaceutical company, we spoke about the current state of affairs—it felt like a cinematic moment unfolding before us. It reminded me of the closing scene of the iconic film Casablanca, when Rick (Humphrey Bogart) tells Captain Renault (Claude Rains): “This is the beginning of a beautiful friendship.” It was a strange, poetic feeling (and in the words of the film Breakfast with Giraffes — dark!) to recall such a legendary line from cinema history right at the gates of a pharmaceutical firm. A year later, when both of our paths had shifted, Dr. Hajimiry graciously agreed to collaborate with us—he became a cherished colleague of our emerging journal, Fansalaran. Respect to him. Turns out, he’s not the type to fuss about rewards or recognition. With remarkable discipline, he contributed columns and articles that became foundational pillars of the journal—without ever...

  Continuous Improvement for Better Outcomes A conversation with Morteza Ayyani, CEO of ChlorPars Company Note: In recent months, ChlorPars Company has taken significant steps—especially in terms of system upgrades, green space development, and equipment overhauls. It has also experienced a notable growth of 15 trillion IRR in the capital market. Here’s our conversation with Morteza Ayyani, CEO of ChlorPars (based in Tabriz), a subsidiary of TPPH (Tamin Pharmaceutical Investment Co.). (Questions have been omitted for brevity.) Morteza Ayyani: As you know, ChlorPars is a technically proficient company producing a wide range of products including perchlorine, ferric chloride, hydrogen peroxide, caustic soda, chlorinated paraffin, caustic potash, sodium hypochlorite, hydrogen, and more. Among these, hydrogen peroxide (industrial grade) and chlorinated paraffin are exclusive to ChlorPars and are produced only by us at a level comparable to international standards like EOP. Over the past two months, we have successfully launched pilot-scale semi-industrial production of food-grade hydrogen peroxide, and we aim to integrate it into full-scale production within the next two months upon receiving the necessary permits. The financial performance of ChlorPars has improved significantly over the past four months, with a valuation increase of 1,000 billion IRR, according to the Securities and Exchange Organization. This success is attributed to strategic...